Zentalis Pharmaceuticals (ZNTL) Enterprise Value (2022 - 2025)
Historic Enterprise Value for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$278.3 million.
- Zentalis Pharmaceuticals' Enterprise Value fell 57350.19% to -$278.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$278.3 million, marking a year-over-year decrease of 57350.19%. This contributed to the annual value of -$351.9 million for FY2024, which is 2711.24% up from last year.
- According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' Enterprise Value is -$278.3 million, which was down 57350.19% from -$286.6 million recorded in Q2 2025.
- Zentalis Pharmaceuticals' Enterprise Value's 5-year high stood at -$30.4 million during Q1 2022, with a 5-year trough of -$482.8 million in Q4 2023.
- In the last 4 years, Zentalis Pharmaceuticals' Enterprise Value had a median value of -$54.8 million in 2022 and averaged -$161.3 million.
- In the last 5 years, Zentalis Pharmaceuticals' Enterprise Value crashed by 102680.17% in 2023 and then surged by 8612.1% in 2024.
- Over the past 4 years, Zentalis Pharmaceuticals' Enterprise Value (Quarter) stood at -$42.8 million in 2022, then tumbled by 1026.8% to -$482.8 million in 2023, then increased by 27.11% to -$351.9 million in 2024, then rose by 20.92% to -$278.3 million in 2025.
- Its Enterprise Value was -$278.3 million in Q3 2025, compared to -$286.6 million in Q2 2025 and -$320.3 million in Q1 2025.